Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.42 |
| ▸ | AURKA | O14965 | 7/20 | 0.42 |
| ▸ | TEK | Q02763 | 7/20 | 0.42 |
| ▸ | LCK | P06239 | 6/20 | 0.42 |
| ▸ | MET | P08581 | 5/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22972205 | 0.90 | LMNA (0.43) | KDRAURKATEKLCKMET | |
| SCHEMBL22971978 | 0.90 | POLB (0.49) | KDRAURKATEKLCKMET | |
| SCHEMBL22972274 | 0.90 | KDR (0.54) | KDRAURKATEKLCKMET | |
| SCHEMBL24724247 | 0.88 | KDR (0.43) | KDRAURKATEKLCKMET | |
| SCHEMBL22972408 | 0.86 | KDR (0.41) | KDRAURKATEKLCKMET | |
| SCHEMBL22972407 | 0.85 | PDGFRB (0.43) | KDRAURKATEKLCKMET | |
| SCHEMBL22972271 | 0.85 | CCR1 (0.42) | KDRAURKATEKLCKMET | |
| SCHEMBL22972168 | 0.85 | KDR (0.42) | KDRAURKATEKLCKMET | |
| SCHEMBL22972169 | 0.84 | KDR (0.42) | KDRAURKATEKLCKMET | |
| SCHEMBL24723956 | 0.83 | NSD2 (0.50) | GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2022-12-08 | — | — | US | disclosed |
| WO-2021023888-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | B.C.I. PHARMA (BE) | 2021-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388979-A1 | QUINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABL1, PHKB, EEF2K | KDR 604/4885AURKA 245/4885TEK 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.